Skip to content

Pila Pharma AB is a clinical stage biotech company developing a potent, selective TRPV1 antagonist, XEN-D0501, as treatment of the rare painful disease erythromelalgia, type 2 diabetes and obesity.

Pila Pharma is currently preparing for a capital raise to sponsor the next 2 phase 2a clinical trials with XEN-D0501:

A study in obese people with type 2 diabetes to explore safety of higher doses and 3 months treatment and possible effects on lowering blood glucose and bodyweight

A study in people with the rare disease erythromelalgia to explore effect on perceived pain

XEN-D0501 has been tested in 300 subjects in phase 1 and 2 and has a demonstrated good safety profile in healthy volunteers and in patients with overactive bladder disease, chronic cough or type 2 diabetes as well as efficacy in type 2 diabetics on improving glucose stimulated insulin secretion.
Recently, 13 week preclinical safety studies with XEN-D0501 completed without registration of side effects and the molecule can therefore progress to clinical trials of up to 3 months duration.

In July 2022, the company received US Orphan Drug Designation for XEN-D0501 as treatment as the rare and painful disease erythromelalgia.

The company is based in Malmö, Sweden and is listed on Nasdaq First North GM, Stockholm, since July 2021.
The company is whole owner of private Danish subsidiary Pila Pharma Danmark ApS, Denmark.
The company welcomes partners and investors for the next development stages.

LATEST COMPANY PRESENTATIONS AND INTERVIEWS

PIla Pharma CEO Dorte X. Gram discusses with financial markets expert Richard Busellato on the obesity market, considerations of investing in pharma and how future solutions could look like including Pila Pharma’s novel tablet based #TRPV1-antagonist treatment

Please, find the link to the video (in English) here

(01 December-2023)

Our CEO Dorte X. Gram presented the Company and ongoing Rights Issue at Aktiespararna event Stora Aktiedagen i Stockholm

Please, find the link to the video (in English) here

(27 November-2023)

Our CEO Dorte X. Gram presented the Company and ongoing Rights Issue to the Danish young-investor group “Unge Investorer”

Please, find the link to the video (in Denish) here

(27 November-2023)

Our CEO Dorte X. Gram presents at Redeye Life Science Day 2023

Please, find the link to the video (in English) here

(23 November-2023)

Proinvestor – Pila Pharma vil lave en tablet mod fedme og diabetes
En mere teknisk introduktion til PILA PHARMA

For more information, please visit the following link here

(16 November-2023)

Today we paid a visit to the impressive clinical site in Cambridge where we plan to carry out our next phase 2 trial with XEN-D0501 in obese people with diabetes.
Happy worlddiabetesday to all!

Please, find the link to the video (in English) here

(14 November-2023)

CEO & Founder Dorte X. Gram presents PILA PHARMA’s innovative take on an alternative route to treating obesity, diabetes and cardiovascular disease at the LSX Inv€$tival conference in London.

Please, find the link to the video (in English) here

(13 November-2023)

Dansk Aktionærforening: Kom med på rejsen mod mere effektiv fedmebehandling
En god introduktion til PILA PHARMA

For more information, please visit the following link here

(07 November-2023)

Presentation by PILA PHARMA CEO, Dr. Dorte X. Gram at the LSXNordic Congress on 11/10/2023 on the case of TRPV1 antagonist XEN-D0501 as a novel treatment of obesity and type-2 diabetes.

In the presentation, Dr. Gram presents some previously undisclosed data on a heartfailure marker (ANP) further strengthening the case for XEN-D0501 as a safe and potent molecule for its class with benificial cardiometabolic effects.

Please, find the link to the video (in English) here
(19 Oct-2023)
Pila Pharma ProHearings
Our CEO Dorte X Gram visited ProHearings on 23-09-29 and gave an investor presentation.
Please, find the link to the video (in English) here
(03 Oct-2023)
QU Life Science
Yesterday, our CEO Dorte Xenia Gram had the pleasure of presenting a deep-dive in the history of PILA PHARMA PILA to Danish investors, where we fit in with the new obesity & diabetes treatments and some previously undisclosed positive data on a heartfailure marker! 😉
Please, find the link to the video (in Danish) here
(29 Sep-2023)
Financial Stockholm

On August 28, 2023 in Finans Stockholm, our CEO For Dorte X Gram gave some hints at how PILA PHARMA will proceed and be relevant with our TRPV1 antagonist treatment.

Please, find the link to the video (in English) here

(07 Sep-2023)

Live from San Diego! Takeaways from this years ADA2023, the American Diabetes association yearly congress.
Hear our CEO, Dorte X. Gram’s thoughts on the trends and developments in the diabetes and obesity space.
Please, find the link to the video (in English) here

(27 June-2023)

CEO of Pila Pharma, Dorte X. Gram, interviews Matt Sondag about the thoughts and challenges of a living with erythromelalgia, a rare disease with periods of intense pain.
Please, find the link to the video (in English) here

(2 June-2023)

News

Pila Pharma AB announces outcome in the rights issue

Read the press release (in English) here

(05 Dec-2023)
THE ONGOING RIGHTS ISSUE IN PILA PHARMA HAS ENTERED ITS LAST SUBSCRIPTION WEEK AND WILL END MONDAY 4 DECEMBER. THE LAST DAY OF TRADING SUBSCRIPTION RIGHTS IS WEDNESDAY 29 NOVEMBER
Read the press release (in English) here
(29 Nov-2023)

PILA PHARMA WILL PRESENT AT “STORA AKTIEDAGARNA” IN STOCKHOLM TOMORROW, 27 NOVEMBER 2023 AT 8:00 CET
Read the press release (in English) here

(26 Nov-2023)

PILA PHARMA ANNOUNCES PRECLINICAL RESEARCH COLLABORATION
Read the press release (in English) here

(26 Nov-2023)
PILA PHARMA PUBLISHES INFORMATION MEMORANDUM

Read the press release (in English) here

(17 Nov-2023)
Pila Pharma invites to After-Work investor meetings

Read the press release (in English) here

(07 Nov-2023)

PILA PHARMA PUBLISHES INTERIM REPORT (1 July – 30 September 2023)

Read the press release (in English) here

(25 Oct-2023)

PILA PHARMA’S BOARD OF DIRECTORS HAS RESOLVED TO CARRY OUT A RIGHTS ISSUE OF SHARES OF APPROXIMATELY SEK 26.2 MILLION

Read the press release (in English) here

(25 Oct-2023)
Back To Top